Top Growth Companies With High Insider Ownership

As global markets show mixed performance amid light trading and inflation data nearing central bank targets, investors are increasingly looking for resilient growth opportunities. In this environment, companies with high insider ownership often stand out as they indicate strong confidence from those who know the business best.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3)	11.9%	20.3%
Atlas Energy Solutions (NYSE:AESI)	29.1%	42.1%
People & Technology (KOSDAQ:A137400)	16.5%	35.6%
KebNi (OM:KEBNI B)	37.8%	86.1%
Calliditas Therapeutics (OM:CALTX)	12.7%	51.9%
Credo Technology Group Holding (NasdaqGS:CRDO)	14.1%	60.9%
Adocia (ENXTPA:ADOC)	11.9%	63%
Adveritas (ASX:AV1)	21.1%	144.2%
EHang Holdings (NasdaqGM:EH)	32.8%	78.8%
UTI (KOSDAQ:A179900)	33.1%	134.6%

Click here to see the full list of 1503 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Central Puerto (BASE:CEPU)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Central Puerto S.A. is involved in electric power generation in Argentina, with a market cap of ARS1.75 trillion.

Operations: Central Puerto's revenue segments include ARS273.39 billion from electric power generation from conventional sources, ARS63.26 billion from renewable sources, ARS184.47 billion from the transportation, distribution and marketing of natural gas, and ARS10.82 million from forest activities.

Insider Ownership: 27.4%

Central Puerto shows strong growth potential with high insider ownership, evidenced by its substantial earnings increase of 201.4% over the past year and forecasted annual earnings growth of 120.2%. The company trades at a favorable price-to-earnings ratio of 11.2x compared to the AR market's 19.6x, indicating good value relative to peers. Recent financial results reveal significant revenue growth, with sales reaching ARS 306 billion for the first half of 2024, up from ARS 265 billion a year ago.

• Click here to discover the nuances of Central Puerto with our detailed analytical future growth report.
• Insights from our recent valuation report point to the potential undervaluation of Central Puerto shares in the market.

Ningbo Jifeng Auto Parts (SHSE:603997)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Ningbo Jifeng Auto Parts Co., Ltd. manufactures automotive interior parts in China and has a market cap of CN¥14.25 billion.

Operations: The company's revenue segments include the production of automotive interior parts in China.

Insider Ownership: 25.7%

Ningbo Jifeng Auto Parts has seen significant insider ownership changes recently, with Yu Wanli and Wang Jimin acquiring substantial stakes totaling 16.18% for a combined CNY 1.9 billion. Despite a dip in net income to CNY 53.14 million for H1 2024, the company shows strong growth potential with forecasted annual earnings growth of 66%, outpacing the CN market's average of 23.1%. However, interest payments are not well covered by earnings, indicating financial strain.

• Click to explore a detailed breakdown of our findings in Ningbo Jifeng Auto Parts' earnings growth report.
• The valuation report we've compiled suggests that Ningbo Jifeng Auto Parts' current price could be quite moderate.

Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076)

Simply Wall St Growth Rating: ★★★★★★

Overview: Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. is a biomedical company involved in the research, development, production, sale, and technical service of peptides and small molecule drugs in China, with a market cap of CN¥13.11 billion.

Operations: The company's revenue segments include the research and development, production, sale, and technical service of peptides and small molecule drugs in China.

Insider Ownership: 15.7%

Jiangsu Sinopep-Allsino Biopharmaceutical reported impressive earnings for H1 2024, with sales reaching CNY 831.5 million and net income at CNY 227.16 million, both significantly higher than the previous year. The company’s earnings are forecast to grow by 33.52% annually, outpacing the CN market's average of 23.1%. Despite some shareholder dilution over the past year and a highly volatile share price, its high insider ownership signals strong internal confidence in its growth trajectory.

• Navigate through the intricacies of Jiangsu Sinopep-Allsino Biopharmaceutical with our comprehensive analyst estimates report here.
• Upon reviewing our latest valuation report, Jiangsu Sinopep-Allsino Biopharmaceutical's share price might be too optimistic.

Turning Ideas Into Actions

• Discover the full array of 1503 Fast Growing Companies With High Insider Ownership right here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com